- In September 2024, Embecta Corp., a global leader in diabetes care with a century-long history in insulin delivery, has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative disposable insulin delivery system. Designed for adults managing diabetes, including both type 1 (T1D) and type 2 (T2D), this system features a tubeless patch pump design equipped with a 300-unit insulin reservoir, developed based on insights from individuals with T2D and their healthcare providers
- In March 2024, The FDA has cleared the twiist Automated Insulin Delivery (AID) system, marking it as the first insulin pump to integrate with Tidepool Loop. Approved for individuals with type 1 diabetes aged 6 and older, the twiist AID system, in conjunction with Tidepool Loop, provides precise microdosing capabilities, allows users to set a target as low as 87 mg/dL, and offers bolusing options based on various food types
- In January 2024, Medtronic plc, a global frontrunner in healthcare technology, has announced that it has received CE (Conformité Européenne) Mark approval for the MiniMed™ 780G system, which includes Simplera Sync, a disposable, all-in-one continuous glucose monitor (CGM) that eliminates the need for fingersticks or overtape. The Simplera Sync offers an enhanced user experience with a straightforward two-step insertion process and is half the size of earlier Medtronic sensors
- In December 2023, Medtronic has canceled its plans to acquire EOFlow, a company that manufactures an insulin patch pump currently involved in a patent dispute with Insulet. Medtronic cited “multiple breaches” of the agreements between the two companies as the reason for the decision. This year, EOFlow has faced ongoing patent litigation with Insulet
- In May 2023, Embecta has partnered with Tidepool to collaborate on the development of an innovative insulin pump designed to enhance diabetes management. This strategic alliance aims to integrate advanced technology and user-friendly features into the device, improving patient outcomes. In addition, Embecta has raised its growth outlook for the second quarter, reflecting confidence in its product pipeline and market demand
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Patch pumps and Tethered pumps), Products (MiniMed, Accu-Chek, Tandem, Omnipod, and Others), Accessories (Insulin Reservoirs or Cartridges, Insulin Set Insertion Devices, and Batteries), End User (Hospitals and Clinics, Home Care, and Laboratories) – Industry Trends and Forecast to 2031
.
The Global Disposable Insulin Pumps Market size was valued at USD 3.57 USD Billion in 2023.
The Global Disposable Insulin Pumps Market is projected to grow at a CAGR of 7.77% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
